कंपनी का अवलोकन
Cytosorbents Corporation is a medical device manufacturer focused on the research, development, and commercialization of blood purification technology platforms that utilize proprietary adsorbent and porous polymer solutions across the United States, Germany, and international markets. The enterprise operates within the Healthcare sector, specifically targeting the Medical Devices industry, which implies a specialized focus on equipment essential for clinical diagnostics and therapeutic procedures. This organization employs a workforce of 129 individuals and maintains a total market capitalization of $37.99M alongside an annual revenue run rate of $37.06M for the trailing twelve months. The relatively small market cap and revenue figures indicate that the company occupies a niche position within the broader healthcare landscape, suggesting limited market share compared to large-cap pharmaceutical or device conglomerates.
वित्तीय स्वास्थ्य
For the trailing twelve months, the company reported a revenue of $37.06M while posting a net income of $-8,198,000 and an EBITDA of $-12,743,000. The substantial gap between the positive revenue of $37.06M and the negative net income of $-8.198M reveals a cost structure characterized by significant operating expenses or non-operating losses that outweigh gross profits. The free cash flow stands at $-2,071,875, indicating that current cash generation is insufficient to cover capital expenditures and working capital requirements, which constrains immediate financial flexibility for strategic acquisitions or debt repayment without external funding. Margin analysis shows a Gross Margin of 71.5%, which suggests high pricing power or low cost of goods sold relative to revenue, yet this is offset by an Operating Margin of -43.9% and a Profit Margin of -22.1%, highlighting severe inefficiencies in overhead management or high research and development costs. The balance sheet presents a leveraged profile with total debt of $29.11M against cash reserves of $6.25M, resulting in a Debt to Equity ratio of 493.16, which signals a high reliance on borrowed capital relative to shareholder equity. Liquidity is supported by a Current Ratio of 2.12, indicating that the company holds more than double the current assets required to meet short-term obligations, though this buffer is pressured by the negative operating performance. Return on Equity is recorded at -96.4% and Return on Assets at -19.4%, metrics that reveal management effectiveness has been negative, as the entity is currently destroying shareholder value and failing to generate returns on its asset base.
मूल्यांकन आकलन
The trailing twelve-month P/E Ratio is listed as N/A due to negative earnings, while the Forward P/E is inf, implying that the market prices the stock based on anticipated future profitability rather than current performance. The Price to Book ratio stands at 6.44, indicating that the market values the company at a significant premium over its book value, which may reflect expectations of future turnaround or asset revaluation despite current losses. Alternative valuation metrics such as a Price to Sales ratio of 1.03 and an EV/EBITDA of -4.77 suggest that investors are willing to pay approximately one dollar for every dollar of sales, though the negative EV/EBITDA underscores the lack of current earnings power. The stock trades within a 52-week range bounded by a high of $1.39 and a low of $0.50; without the current specific share price, the position relative to this range cannot be mathematically calculated from the provided data, but the spread indicates high historical volatility. The Beta value of 1.48 demonstrates that the stock price is significantly more volatile than the broader market, moving 48% more than the index on average during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year is recorded at 0.9%, whereas earnings growth is N/A due to the company's persistent net losses, indicating that top-line sales are expanding while profitability remains elusive. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the firm retains all available cash flow to reinvest into its blood purification technology platform rather than distributing income to shareholders. The absence of a dividend payout ratio implies that the company prioritizes capital expenditure for research and development over immediate income generation for investors. Overall, the growth and income profile is defined by modest revenue expansion paired with deep losses and no dividend income, reflecting a high-risk, high-potential-growth trajectory typical of early-stage biotechnology and medical device firms.